瑞康医药
(002589)
| 流通市值：39.06亿 | | | 总市值：43.03亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,141,519,673 | 3,414,747,352.56 | 1,707,482,764.51 | 7,295,858,461.63 |
| 营业收入 | 5,141,519,673 | 3,414,747,352.56 | 1,707,482,764.51 | 7,295,858,461.63 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 5,141,599,300.89 | 3,418,218,716.66 | 1,692,322,269.95 | 7,353,302,934.53 |
| 营业成本 | 4,549,311,272.39 | 3,026,388,315.71 | 1,489,245,910.43 | 6,519,801,097.22 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 25,642,082.9 | 16,849,219.97 | 8,647,389.44 | 36,644,988.6 |
| 销售费用 | 215,627,020.72 | 134,663,827.93 | 55,225,875.51 | 328,917,549.86 |
| 管理费用 | 250,914,162.73 | 155,252,637.99 | 88,916,157.33 | 330,689,392.55 |
| 研发费用 | 8,055,591.24 | 6,196,293.57 | 2,711,920.75 | 20,910,773.07 |
| 财务费用 | 92,049,170.91 | 78,868,421.49 | 47,575,016.49 | 116,339,133.23 |
| 其中:利息费用 | 125,830,455.03 | 94,896,124.55 | 55,316,940.92 | 178,997,925.7 |
| 其中:利息收入 | 36,569,493.42 | 18,231,273 | 9,658,254.45 | 78,212,074.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 0 | 4,902,905.63 |
| 加:投资收益 | 24,882,100.05 | 6,013,442.28 | 1,297,098.79 | 84,806,805.99 |
| 资产处置收益 | 231,675.45 | 188,559.16 | 88,849.32 | 1,817,272.56 |
| 资产减值损失(新) | - | - | 0 | - |
| 信用减值损失(新) | 12,948,921.22 | 35,843,573.03 | -158,423.18 | -26,501,315.05 |
| 其他收益 | 3,471,861.49 | 129,732.84 | 63,059.41 | 9,270,217.24 |
| 四、营业利润 | 41,454,930.32 | 38,703,943.21 | 16,451,078.9 | 16,851,413.47 |
| 加:营业外收入 | 669,738.4 | 642,435.95 | 308,730.45 | 4,195,902.18 |
| 减:营业外支出 | 3,066,054.91 | 1,285,126.33 | 443,151.16 | 18,360,066.96 |
| 五、利润总额 | 39,058,613.81 | 38,061,252.83 | 16,316,658.19 | 2,687,248.69 |
| 减:所得税费用 | 4,021,074.23 | 7,724,389.36 | 697,096.09 | -41,214,881.56 |
| 六、净利润 | 35,037,539.58 | 30,336,863.47 | 15,619,562.1 | 43,902,130.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 35,037,539.58 | 30,336,863.47 | 15,619,562.1 | 43,902,130.25 |
| 终止经营净利润 | - | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,262,667.02 | 11,135,298.13 | 10,372,213.68 | 16,071,175.45 |
| 少数股东损益 | 25,774,872.56 | 19,201,565.34 | 5,247,348.42 | 27,830,954.8 |
| 扣除非经常损益后的净利润 | -16,840,796.44 | 5,414,219.86 | 9,145,523.65 | -64,103,305.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.01 | 0.01 | 0.01 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0.01 | 0.01 |
| 九、综合收益总额 | 35,037,539.58 | 30,336,863.47 | 15,619,562.1 | 43,902,130.25 |
| 归属于母公司股东的综合收益总额 | 9,262,667.02 | 11,135,298.13 | 10,372,213.68 | 16,071,175.45 |
| 归属于少数股东的综合收益总额 | 25,774,872.56 | 19,201,565.34 | 5,247,348.42 | 27,830,954.8 |
| 公告日期 | 2026-10-27 | 2026-08-21 | 2026-04-25 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |